Emricasan

Drug Profile

Emricasan

Alternative Names: IDN-6556; PF-03491390; PF-3,491,390

Latest Information Update: 29 Mar 2017

Price : $50

At a glance

  • Originator Idun Pharmaceuticals
  • Developer Conatus Pharmaceuticals
  • Class Amides; Antifibrotics; Fluorobenzenes; Hepatoprotectants; Pentanoic acids; Phenyl ethers; Small molecules
  • Mechanism of Action Apoptosis inhibitors; Caspase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatic fibrosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Portal hypertension
  • Phase I/II Type 1 diabetes mellitus
  • Suspended Alcoholic hepatitis; Liver failure
  • No development reported Liver disorders
  • Discontinued Septic shock

Most Recent Events

  • 15 Mar 2017 Conatus Pharmaceuticals plans the phase IIb ENCORE-LF trial for decompensated non-alcoholic steatohepatitis cirrhosis, in the second quarter of 2017
  • 19 Dec 2016 Novartis plans to conduct multiple phase IIb trials for Non-alcoholic steatohepatitis
  • 19 Dec 2016 Conatus enters into an exclusive option, collaboration and license agreement with Novartis to co-develop and co-promote emricasan in countries worldwide for Non-alcoholic steatohepatitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top